{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:19:06Z","timestamp":1778685546097,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00520-026-10642-w","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:12:49Z","timestamp":1777007569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiac adverse events associated with axitinib: A real-world pharmacovigilance study based on the Japanese adverse drug event report database"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8882-8846","authenticated-orcid":false,"given":"Keiko","family":"Hosohata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riku","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0095-2293","authenticated-orcid":false,"given":"Yuko","family":"Kanbayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"10642_CR1","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI24612","volume":"116","author":"MR Mancuso","year":"2006","unstructured":"Mancuso MR, Davis R, Norberg SM, O\u2019Brien S, Sennino B, Nakahara T et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610\u20132621","journal-title":"J Clin Invest"},{"key":"10642_CR2","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K et al (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272\u20137283","journal-title":"Clin Cancer Res"},{"key":"10642_CR3","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/bjc.2013.145","volume":"108","author":"D Cella","year":"2013","unstructured":"Cella D, Escudier B, Rini B, Chen C, Bhattacharyya H, Tarazi J et al (2013) Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer 108:1571\u20131578","journal-title":"Br J Cancer"},{"key":"10642_CR4","doi-asserted-by":"crossref","unstructured":"Ritter K, Strojny M, McCullough J, Law J (2025) Real-world efficacy and tolerability of axitinib + pembrolizumab in the treatment of renal cell carcinoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners: 10781552251331576. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40325928","DOI":"10.1177\/10781552251331576"},{"key":"10642_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1585862","volume":"16","author":"L Li","year":"2025","unstructured":"Li L, Bai J, Wen X, Zeng X (2025) Adverse reactions of four multi-targeted tyrosine kinase inhibitors: a descriptive analysis of the WHO-VigiAccess database. Front Pharmacol 16:1585862","journal-title":"Front Pharmacol"},{"key":"10642_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40261-019-00788-3","volume":"39","author":"K Hosohata","year":"2019","unstructured":"Hosohata K, Oyama S, Niinomi I, Wakabayashi T, Inada A, Iwanaga K (2019) Comparison of safety profiles of new oral anticoagulants with warfarin using the Japanese Spontaneous Reporting Database. Clin Drug Investig 39:665\u2013670","journal-title":"Clin Drug Investig"},{"key":"10642_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/1091581819870717","volume":"38","author":"I Niinomi","year":"2019","unstructured":"Niinomi I, Hosohata K, Oyama S, Inada A, Wakabayashi T, Iwanaga K (2019) Pharmacovigilance assessment of drug-induced acute pancreatitis using a spontaneous reporting database. Int J Toxicol 38:487\u2013492","journal-title":"Int J Toxicol"},{"key":"10642_CR8","doi-asserted-by":"crossref","unstructured":"Inada A, Hosohata K, Oyama S, Niinomi I, Mori Y, Yamaguchi Y et al (2019) Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database. Therapeutics and clinical risk management 15: 59\u201364. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30636879","DOI":"10.2147\/TCRM.S176620"},{"key":"10642_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.31083\/ph.2020.0604","volume":"75","author":"H Kambara","year":"2020","unstructured":"Kambara H, Hosohata K, Nakatsuji T, Ueno S, Oyama S, Inada A et al (2020) Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study. Pharmazie 75:527\u2013530","journal-title":"Pharmazie"},{"key":"10642_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.5414\/CP203898","volume":"59","author":"T Wakabayashi","year":"2021","unstructured":"Wakabayashi T, Ueno S, Nakatsuji T, Hirai T, Niinomi I, Oyama S et al (2021) Safety profiles of new xanthine oxidase inhibitors: a post-marketing study. Int J Clin Pharmacol Ther 59:372\u2013377","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10642_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.5414\/CP204016","volume":"59","author":"H Kambara","year":"2021","unstructured":"Kambara H, Oyama S, Inada A, Niinomi I, Wakabayashi T, Hosohata K (2021) Current status of adverse event profile of tacrolimus in patients with solid organ transplantation from a pharmacovigilance study. Int J Clin Pharmacol Ther 59:753\u2013759","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10642_CR12","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2147\/TCRM.S168696","volume":"14","author":"S Oyama","year":"2018","unstructured":"Oyama S, Hosohata K, Inada A, Niinomi I, Mori Y, Yamaguchi Y et al (2018) Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database. Ther Clin Risk Manag 14:1599\u20131604","journal-title":"Ther Clin Risk Manag"},{"key":"10642_CR13","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.2147\/OPTH.S439255","volume":"17","author":"M Kozaru","year":"2023","unstructured":"Kozaru M, Iida T, Hosohata K (2023) A pharmacovigilance study of drug-induced glaucoma utilizing the Japanese Adverse Event Reporting System. Clin Ophthalmol 17:3645\u20133653","journal-title":"Clin Ophthalmol"},{"key":"10642_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2147\/VHRM.S482190","volume":"20","author":"M Kozaru","year":"2024","unstructured":"Kozaru M, Kambara H, Higuchi A, Kagatsume T, Hosohata K (2024) Association of clopidogrel with interstitial lung disease: gaining insight through the Japanese Pharmacovigilance Database. Vasc Health Risk Manag 20:415\u2013420","journal-title":"Vasc Health Risk Manag"},{"key":"10642_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3\u201310","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10642_CR16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR (2013) Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf 36:995\u20131006","journal-title":"Drug Saf"},{"key":"10642_CR17","doi-asserted-by":"publisher","first-page":"101415","DOI":"10.1016\/j.ijcha.2024.101415","volume":"52","author":"A Dilli Babu","year":"2024","unstructured":"Dilli Babu A, Singh S, Thota A, Duhan S, Sainatham C, Gill H et al (2024) Systemic hypertension with VEGFR inhibitor (axitinib) therapy in cancer patients: a meta-analysis and systematic review of randomized controlled trials. Int J Cardiol Heart Vasculature 52:101415","journal-title":"Int J Cardiol Heart Vasculature"},{"key":"10642_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1223929","volume":"14","author":"K Krawczyk","year":"2023","unstructured":"Krawczyk K, Sladowska K, Holko P, Kawalec P (2023) Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. Front Pharmacol 14:1223929","journal-title":"Front Pharmacol"},{"key":"10642_CR19","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1016\/j.clgc.2021.03.019","volume":"19","author":"BI Rini","year":"2021","unstructured":"Rini BI, Atkins MB, Choueiri TK, Thomaidou D, Rosbrook B, Thakur M et al (2021) Time to resolution of axitinib-related adverse events after treatment interruption in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 19:e306\u2013e312","journal-title":"Clin Genitourin Cancer"},{"key":"10642_CR20","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s00432-021-03521-w","volume":"147","author":"W Hou","year":"2021","unstructured":"Hou W, Ding M, Li X, Zhou X, Zhu Q, Varela-Ramirez A et al (2021) Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. J Cancer Res Clin Oncol 147:2407\u20132420","journal-title":"J Cancer Res Clin Oncol"},{"key":"10642_CR21","doi-asserted-by":"crossref","unstructured":"Van Leeuwen MT, Luu S, Gurney H, Brown MR, Pearson SA, Webber K et al (2020) Cardiovascular toxicity of targeted therapies for cancer: an overview of systematic reviews. JNCI cancer spectrum 4: pkaa076. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33392444","DOI":"10.1093\/jncics\/pkaa076"},{"key":"10642_CR22","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Soulieres D, Waddell T, Stus V, Gafanov R et al (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 21:1563\u20131573","journal-title":"Lancet Oncol"},{"key":"10642_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/JCMA.0000000000001026","volume":"87","author":"YC Chen","year":"2024","unstructured":"Chen YC, Chen JH, Hsieh FI (2024) Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: a systemic review and network meta-analysis. J Chin Med Assoc JCMA 87:48\u201357","journal-title":"J Chin Med Assoc JCMA"},{"key":"10642_CR24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-021-00817-2","volume":"16","author":"A Goldman","year":"2021","unstructured":"Goldman A, Bomze D, Dankner R, Fourey D, Boursi B, Arad M et al (2021) Cardiovascular toxicities of antiangiogenic tyrosine kinase inhibitors: a retrospective, pharmacovigilance study. Target Oncol 16:471\u2013483","journal-title":"Target Oncol"},{"key":"10642_CR25","doi-asserted-by":"publisher","first-page":"865","DOI":"10.20344\/amp.21306","volume":"37","author":"J Queiros Coelho","year":"2024","unstructured":"Queiros Coelho J, Simoes J, Fonseca T, Xavier Azevedo S, Araujo A (2024) Fatal case of immune-related myocarditis and myositis due to treatment with immune checkpoint and tyrosine kinase inhibitors. Acta Med Port 37:865\u2013868","journal-title":"Acta Med Port"},{"key":"10642_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1159\/000545733","volume":"18","author":"J Karibe","year":"2025","unstructured":"Karibe J, Horiguchi R, Hanajima Y, Hashizume A, Takamoto D, Kawahara T et al (2025) A case of immune-related adverse events, including myasthenia gravis, myositis, and myocarditis, during avelumab and axitinib combination therapy. Case Rep Oncol 18:563\u2013569","journal-title":"Case Rep Oncol"},{"key":"10642_CR27","volume":"9","author":"J Del Cid Fratti","year":"2023","unstructured":"Del Cid Fratti J, Paleru V, Bajaj M, Bhardwaj C (2023) The toxic tango: TKI and TCI cardiotoxicities. Cardio-Oncol 9:44","journal-title":"Cardio-Oncol"},{"key":"10642_CR28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejca.2018.06.021","volume":"101","author":"AM Berner","year":"2018","unstructured":"Berner AM, Sharma A, Agarwal S, Al-Sam S, Nathan P (2018) Fatal autoimmune myocarditis with anti-PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer. Eur J Cancer 101:287\u2013290","journal-title":"Eur J Cancer"},{"key":"10642_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejca.2019.09.009","volume":"124","author":"CW Guo","year":"2020","unstructured":"Guo CW, Alexander M, Dib Y, Lau PKH, Weppler AM, Au-Yeung G et al (2020) A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. Eur J Cancer 124:15\u201324","journal-title":"Eur J Cancer"},{"key":"10642_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-019-1225-6","volume":"21","author":"CK Ala","year":"2019","unstructured":"Ala CK, Klein AL, Moslehi JJ (2019) Cancer treatment-associated pericardial disease: epidemiology, clinical presentation, diagnosis, and management. Curr Cardiol Rep 21:156","journal-title":"Curr Cardiol Rep"},{"key":"10642_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1472008","volume":"15","author":"Y Igawa","year":"2024","unstructured":"Igawa Y, Hamano H, Esumi S, Takeda T, Kajizono M, Kikuoka R et al (2024) Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database. Front Pharmacol 15:1472008","journal-title":"Front Pharmacol"},{"key":"10642_CR32","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/1078155220930367","volume":"27","author":"T Mizuno","year":"2021","unstructured":"Mizuno T, Sakai T, Tanabe K, Kozaki K, Umemura T, Higashikawa M et al (2021) Identification of target small molecule tyrosine kinase inhibitors that need monitoring and clinical application of protocol for early detection of cancer therapeutics-related cardiac dysfunction using signal detection: an investigation of real world data. J Oncol Pharm Pract 27:804\u2013814","journal-title":"J Oncol Pharm Pract"},{"key":"10642_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.31083\/ph.2025.4624","volume":"80","author":"Y Kanbayashi","year":"2025","unstructured":"Kanbayashi Y, Kano R, Tsuchiya E, Wakabayashi H, Kawahara Y, Shimizu T et al (2025) Disproportionality analysis of cardiac adverse events associated with sorafenib using Spontaneous Reporting Database in Japanese. Pharmazie 80:29\u201332","journal-title":"Pharmazie"},{"key":"10642_CR34","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1111\/bcp.16237","volume":"90","author":"Y Kanbayashi","year":"2024","unstructured":"Kanbayashi Y, Kobayashi S, Kojima A, Wakabayashi H, Shimizu T, Uchida M (2024) Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database. Br J Clin Pharmacol 90:3348\u20133354","journal-title":"Br J Clin Pharmacol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10642-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:49:00Z","timestamp":1778683740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10642-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10642"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10642-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"461"}}